Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification

被引:14
|
作者
Arch, Jonathan R. S. [1 ]
Trayhurn, Paul [1 ]
机构
[1] Univ Buckingham, Clore Lab, Buckingham MK18 1EG, England
来源
FRONTIERS IN PHYSIOLOGY | 2013年 / 4卷
关键词
thermogenesis; energy expenditure; leanness; anti-obesity drug; genetically modified mouse; sympathomimetic; brown adipose tissue; leptin; BROWN ADIPOSE-TISSUE; BETA-ADRENOCEPTOR AGONIST; DIET-INDUCED OBESITY; INCREASES ENERGY-EXPENDITURE; SYMPATHETIC-NERVE ACTIVITY; ACTIVATED-RECEPTOR-GAMMA; RESTING METABOLIC-RATE; COLD-INDUCED INCREASE; FATTY-ACID OXIDATION; FOOD-INTAKE;
D O I
10.3389/fphys.2013.00064
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Many compounds and genetic manipulations are claimed to confer resistance to obesity in rodents by raising energy expenditure. Examples taken from recent and older literature, demonstrate that such claims are often based on measurements of energy expenditure after body composition has changed, and depend on comparisons of energy expenditure divided by body weight. This is misleading because white adipose tissue has less influence than lean tissue on energy expenditure. Application of this approach to human data would suggest that human obesity is usually due to a low metabolic rate, which is not an accepted view. Increased energy expenditure per animal is a surer way of demonstrating thermogenesis, but even then it is important to know whether this is due to altered body composition (repartitioning), or increased locomotor activity rather than thermogenesis per se. Regression analysis offers other approaches. The thermogenic response to some compounds has a rapid onset and so cannot be due to altered body composition. These compounds usually mimic or activate the sympathetic nervous system. Thermogenesis occurs in, but may not be confined to, brown adipose tissue. It should not be assumed that weight loss in response to these treatments is due to thermogenesis unless there is a sustained increase in 24-h energy expenditure. Thyroid hormones and fibroblast growth factor 21 also raise energy expenditure before they affect body composition. Some treatments and genetic modifications alter the diurnal rhythm of energy expenditure. It is important to establish whether this is due to altered locomotor activity or efficiency of locomotion. There are no good examples of compounds that do not affect short-term energy expenditure but have a delayed effect. How and under what conditions a genetic modification or compound increases energy expenditure influences the decision on whether to seek drugs for the target or take a candidate drug into clinical studies.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Anti-obesity drugs and valvular heart disease
    不详
    DIABETES OBESITY & METABOLISM, 1999, 1 (04): : 255 - 255
  • [32] Anti-obesity drugs: past, present and future
    Rodgers, R. John
    Tschoep, Matthias H.
    Wilding, John P. H.
    DISEASE MODELS & MECHANISMS, 2012, 5 (05) : 621 - 626
  • [33] Serotonergic targets for novel anti-obesity drugs
    Simansky, K. J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 127 - 127
  • [34] Anti-obesity effects in rodents of dietary teasaponin, a lipase inhibitor
    Han, LK
    Kimura, Y
    Kawashima, M
    Takaku, T
    Taniyama, T
    Hayashi, T
    Zheng, YN
    Okuda, H
    INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (10) : 1459 - 1464
  • [35] Anti-obesity effects in rodents of dietary teasaponin, a lipase inhibitor
    L-K Han
    Y Kimura
    M Kawashima
    T Takaku
    T Taniyama
    T Hayashi
    Y-N Zheng
    H Okuda
    International Journal of Obesity, 2001, 25 : 1459 - 1464
  • [36] Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
    Gitanjali Srivastava
    Caroline Apovian
    Current Obesity Reports, 2018, 7 : 147 - 161
  • [37] Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
    Srivastava, Gitanjali
    Apovian, Caroline
    CURRENT OBESITY REPORTS, 2018, 7 (02): : 147 - 161
  • [38] The obesity pipeline: current strategies in the development of anti-obesity drugs
    Dunstan Cooke
    Steve Bloom
    Nature Reviews Drug Discovery, 2006, 5 : 919 - 931
  • [39] The obesity pipeline: current strategies in the development of anti-obesity drugs
    Cooke, Dunstan
    Bloom, Steve
    NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (11) : 919 - 931
  • [40] Cardiovascular Effects of Current and Future Anti-Obesity Drugs
    Comerma-Steffensen, Simon
    Grann, Martin
    Andersen, Charlotte U.
    Rungby, Jorgen
    Simonsen, Ulf
    CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (03) : 493 - 504